In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

GlycoMimetics, Inc.. Trade Record

NASDAQ:GLYC GlycoMimetics, Inc. stock gains 13.77% Exit Feb 1, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart GLYC Jan 17, 2018, priceSeries
About GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.88
Entry Date
Jan 17, 2018
Entry Price
19.65
Sell Date
Feb 1, 2018
Sell Price
22.36
Net Gain
13.77%
Hold Time
11 Trading Days